Recent Finacing
Recent Raise
InxMed is a clinical-stage Nanjing biotech developing stromal microenvironment-targeting therapies, advancing IN10018, an ATP-competitive FAK inhibitor, in multi-indication clinical trials with global development teams and pharma partnerships.
